Ignite Creation Date:
2024-05-06 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05266846
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2022-02-18
Brief Title:
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5ALK
Sponsor:
Hunan Province Tumor Hospital
Organization:
Hunan Province Tumor Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| ALK Gene Mutation |
| Lung Adenocarcinoma |
| Immunotherapy |
Keywords: